DEP

CEO's of health systems and ACO's have the goals of improving the quality of care to patients while driving down cost. All CEO's have something in common, and that's the stumbling blocks that prevent them from attaining those goals.

If I'm a CEO, and some pharma person tells me they can help me remove the inhibitors that I'm facing in attaining those goals, I'm all ears and I'll let them in. Access to execs in C-suite and access to lower level staff are two different things.

 

lol, CEO's are not going to sit down with DE's. Heck, the HSAM's won't even have access to CEO's, and that's the job if the HSAM and not the DE.

 

I’d say it’s the job of whoever can actually get it done.

 

There are quite a few HSAMs who were just promoted from the DE program. I guess an promotion instantly makes you qualified to talk to a CEO. Because now their title is HSAM? No. A DE can do it just like anyone else.

 

Those CEO's of an Accountable Care Organization that are NOT attaining the diabetes federal benchmarks for lower costs and higher quality of patient care are the ones that will likely want to engage with a Novo HSAM. Those that are hitting (or even exceeding) the diabetes benchmarks will be less inclined to talk with Novo.

It behooves any Novo HSAM anywhere to know whether or not the ACO is hitting the federal targets prior to attempting to engage with a CEO.